All In Biotech

Drug Trial Radar · NCT07211633

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab Versus Intravenous Ublituximab in Patients With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

Oct 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • UblituximabBiological

    Administered as an IV infusion.

  • UblituximabBiological

    Administered as an SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of UblituximabTime frame: Up to Week 24

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Banja Luka, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Bihać, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Mostar, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Saravejo, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Tulza, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Pleven, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Plovdiv, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Sofia, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Sofia, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Veliko Tarnovo, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Varaždin, Croatia

  • TG Therapeutics Investigational Trial Site

    Zagreb, Croatia

  • TG Therapeutics Investigational Trial Site

    Brno, Czechia

  • TG Therapeutics Investigational Trial Site

    Hradec Králové, Czechia

  • TG Therapeutics Investigational Trial Site

    Jihlava, Czechia

  • TG Therapeutics Investigational Trial Site

    Ostrava, Czechia

  • TG Therapeutics Investigational Trial Site

    Pardubice, Czechia

  • TG Therapeutics Investigational Trial Site

    Zlín, Czechia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Budapest, Hungary

  • TG Therapeutics Investigational Trial Site

    Budapest, Hungary

  • TG Therapeutics Investigational Trial Site

    Budapest, Hungary

  • TG Therapeutics Investigational Trial Site

    Kaposvár, Hungary

  • TG Therapeutics Investigational Trial Site

    Kistarsca, Hungary

  • TG Therapeutics Investigational Trial Site

    Pécs, Hungary

  • TG Therapeutics Investigational Trial Site

    Shtip, North Macedonia

  • TG Therapeutics Investigational Trial Site

    Skopje, North Macedonia

  • TG Therapeutics Investigational Trial Site

    Kragujevac, Serbia

  • TG Therapeutics Investigational Trial Site

    Niš, Serbia

  • TG Therapeutics Investigational Trial Site

    Cherkasy, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, Ukraine

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.